macos : ARC-520 shows promise in chronic hepatitis B
ARC-520 shows promise in chronic hepatitis B
By: SHARON WORCESTER, Family Practice News Digital Network
November 23, 2015
AT THE LIVER MEETING 2015
Key clinical point: ARC-520, the first RNA interference?based drug to reach patients, produced deep and durable knockdown of viral antigens and DNA in chronic hepatitis B patients in a phase II study.
Major finding: In treatment-naive patients, the best observed quantitative hepatitis B surface antigen (qHBsAg) knockdown was 1.9 log (99%) in HBeAg-pos patients, and 0.7 log in HBeAg-neg patients (mean max, 1.2 log and 1.1 log, respectively).
Data source: A phase II study of 58 CHB patients.
Disclosures: Dr. Yuen reported advisory committee or review panel participation with GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer, and grant or research support from Roche, Bristol-Myers Squibb, Pfizer, and Gilead Science.